Clinical Trial Update: Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma [NA]

View source ↗

Summary

A completed clinical trial evaluating the biological effect of Tarceva (erlotinib) in patients with head and neck squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Institut Claudius Regaud | Conditions: Head and Neck Neoplasms | NA | Status: COMPLETED